ArticleFrontiers in veterinary science2026
A survey of the clinical usage of intra-articular therapeutics in dogs by veterinary practitioners with a focus on non-steroidal therapies.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a degenerative condition of the joint, whose progressive characteristics can lead to significant functional impairment and pain in the canine patient. Interest has increased regarding the use of intra-articular (IA) therapeutics as part of the multimodal management of canine OA. This study aimed to present the clinical experience of surgery and rehabilitation practitioners using these therapeutics to better understand their clinical usage, perceived outcomes, and clinical reasoning for product usage. A survey inquiring about IA injections with a focus on non-steroidal intra-articular therapeutics (NSIATs), including platelet-rich plasma (PRP), autologous conditioned serum (ACS), autologous protein solution (APS), cellular therapy, viscosupplements, and radionuclide, was distributed to canine practitioners. A total of 174 surveys were included in the results. Intra-articular injections were performed by 164 participants. Among these, 144 practitioners used NSIATs. The most common joint injected with steroidal and/or NSIATs was the elbow. The top reason for participants' decision as to which NSIATs they preferentially used was scientific data and articles published regarding the product's safety and efficacy. The most used NSIATs were PRP and viscosupplements, followed by cellular therapy, radionuclides, ACS, and APS. Practitioners reported that the most common reason to use NSIATs, except for APS, was chronic articular pathology needing 'maintenance' or routine injections. Pertaining to the top two most commonly used products, most participants did not combine PRP with other IA therapeutics. In the case of viscosupplements, 40% of the practitioners combined them with corticosteroids. According to the participants' subjective assessment, most of the positive responders presented substantial or some clinical improvement after PRP or viscosupplements administration. As the first survey on this topic of small animal studies, these results provide valuable insights into the use of NSIATs in canines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.